Okay, let's tackle this question. The user provided a question about a neonate born to a hepatitis B-infected mother and the correct treatment. The correct answer is missing, but I need to figure it out.

First, I remember that perinatal transmission of hepatitis B is a big concern. The standard of care for preventing this is giving the newborn both hepatitis B immune globulin (HBIG) and the first dose of the hepatitis B vaccine. This is usually done within 12 hours of birth. The HBIG provides immediate passive immunity, while the vaccine stimulates active immunity.

Now, the options aren't listed here, but common distractors might include giving only the vaccine, only HBIG, or other treatments like antiviral medications. For example, if an option says "HBIG and vaccine," that's correct. If an option lists antiviral drugs like lamivudine, that's incorrect because they're for chronic management, not neonatal prophylaxis. Another wrong option might be just the vaccine without HBIG, which is less effective. Also, maybe giving the vaccine later than 12 hours is a trap, but the question is about the treatment given, not timing.

The core concept here is the prevention of vertical transmission of hepatitis B. The clinical pearl is remembering the combo of HBIG and vaccine. High-yield fact: the first dose of vaccine and HBIG within 12 hours. So the correct answer should be the combination. Let me structure the explanation accordingly, making sure each part is covered as per the user's instructions.

**Core Concept** The prevention of perinatal hepatitis B virus (HBV) transmission involves administering **hepatitis B immune globulin (HBIG)** and the **first dose of hepatitis B vaccine** to neonates born to HBsAg-positive mothers. This dual approach provides immediate passive immunity (HBIG) and stimulates active immunity (vaccine) to block viral replication and establish long-term protection.

**Why the Correct Answer is Right** Administering HBIG within 12 hours of birth neutralizes circulating HBV particles and prevents seeding of the virus into hepatocytes. The hepatitis B vaccine (60–100 µg of recombinant HBsAg) activates the neonate’s immune system to produce anti-HBs antibodies. Combined, this regimen reduces perinatal transmission risk to 200,000 IU/mL) and is adjunctive, not primary prophylaxis.
**Option D:** *No intervention* ensures high transmission risk and fulminant hepatitis in infants.

**Clinical Pearl / High-Yield Fact** **HBIG + first vaccine dose within 12 hours** is the gold standard for perinatal HBV prevention. Never omit HBIG, even in high-risk cases (e.g

✓ Correct Answer: D. Immunoglobulins & hepatitis-B-vaccine